10-Q: Kymera Therapeutics Reports Q1 2026 Financials

Kymera Therapeutics reported increased collaboration revenue and R&D expenses in Q1 2026, with cash reserves projected to last into 2029.

Summary

• Kymera Therapeutics reported collaboration revenue of $34.4 million for the three months ended March 31, 2026, an increase from $22.1 million in the same period of 2025.
• Total operating expenses increased to $118.5 million from $96.5 million year-over-year, driven by higher research and development costs.
• The company reported a net loss of $69.2 million for the quarter, compared to a net loss of $65.6 million in the prior year's first quarter.
• As of March 31, 2026, Kymera Therapeutics had cash, cash equivalents, and marketable securities totaling $1.546 billion, which management believes is sufficient to fund operations into 2029.
• Gilead Sciences exercised its option to license KT-200, a CDK2 degrader, resulting in a $45 million milestone payment expected in Q2 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed sentiment, with positive developments in collaboration revenue and cash runway, but a worsening net loss and increased operating expenses.

Positives

• Collaboration revenue increased by $12.3 million to $34.4 million in Q1 2026 compared to Q1 2025.
• Gilead Sciences exercised its option for KT-200, triggering a $45 million milestone payment expected in Q2 2026.
• The company's cash, cash equivalents, and marketable securities stand at $1.546 billion as of March 31, 2026, providing a strong liquidity position.
• Management anticipates that current cash reserves will be sufficient to fund operations into 2029, covering multiple clinical inflection points.

Negatives

• Net loss for the first quarter of 2026 was $69.2 million, an increase from $65.6 million in the first quarter of 2025.
• Research and development expenses increased by $17.9 million to $98.2 million in Q1 2026 compared to Q1 2025.
• General and administrative expenses also rose by $4.1 million to $20.4 million in Q1 2026 compared to Q1 2025.
• The company has incurred significant operating losses since inception and anticipates continued losses for the foreseeable future.

Risks

• The company is a clinical-stage company with no approved products, making future viability difficult to assess.
• Significant operating losses have been incurred, and continued losses are anticipated for the foreseeable future.
• Substantial additional funding will be required; failure to raise capital could force delays or discontinuation of development programs.
• The novel and unproven approach to drug discovery and development makes predicting time, cost, and success difficult.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent regulatory approvals.
• Positive results from early studies are not necessarily predictive of later-stage trial outcomes.
• The company relies on third parties for preclinical and clinical trial conduct, and their failure to perform could harm the business.
• Failure to obtain and maintain patent protection could allow competitors to develop similar products.
• Unstable global economic and geopolitical conditions could adversely affect the business.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities of $1.546 billion as of March 31, 2026, will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these condensed consolidated financial statements, and expects them to be sufficient to fund operations into 2029, beyond multiple clinical inflection points.

Management Comments

• We believe there are more than 160 million patients in the United States, Europe and Japan that are diagnosed with some of the most prevalent immune-inflammatory diseases that our programs have the potential to address, nearly half of whom remain untreated.
• We believe we have the potential to deliver a compelling value proposition to a significant underserved patient population: small molecule medicines with biologics-like activity through the convenience of a daily, oral pill.
• We expect that our expense and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: initiate and complete preclinical studies and clinical trials for current or future product candidates; prepare and submit Investigational New Drug applications, or INDs, with the U.S Food and Drug Administration, or FDA, for future product candidates; develop and scale up our capabilities to support our ongoing preclinical activities and clinical trials for our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval; secure facilities to support continued growth in our research, development and commercialization efforts; advance research and development related activities to expand our product pipeline; expand and improve the capabilities of our drug discovery platform; seek regulatory approval for our product candidates that successfully complete clinical development; contract to manufacture our product candidates; maintain, expand and protect our intellectual property portfolio; hire additional staff, including clinical, scientific and management personnel; and incur additional costs associated with continuing to operate as a public company.

Industry Context

StockSavvy.ai notes that Kymera Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on targeted protein degradation. The company's strategy to develop oral small molecule medicines with biologics-like activity addresses a market need for more convenient and potentially cost-effective treatments compared to injectables. The increasing R&D spend is typical for clinical-stage biotechs aiming to advance their pipelines.

Comparison to Industry Standards

• Kymera's net loss of $69.2 million for the quarter is in line with many clinical-stage biopharmaceutical companies that are investing heavily in R&D without significant product revenue.
• The company's cash burn rate of approximately $88.8 million in operating activities for the quarter, while substantial, is supported by a significant cash balance of $1.546 billion, providing an estimated runway into 2029, which is generally considered a strong position for a company at this stage.
• The increase in collaboration revenue from Sanofi to Gilead reflects the company's ability to secure strategic partnerships, a common and crucial element for funding drug development in the industry.

Legal Proceedings

• The Company is not currently a party to any legal proceedings that, in the opinion of its management, are likely to have a material adverse effect on its business.

Related Party Transactions

• The company entered into an Open Market Sale Agreement with Jefferies LLC, where Jefferies acted as sales agent. The agreement was terminated in February 2026, and no shares were sold under it.

Stakeholder Impact

• Shareholders may experience dilution if equity awards or warrants are exercised.
• The company's ability to fund operations into 2029 provides some assurance to investors regarding its near-to-medium term viability.
• Increased R&D spending may lead to future product development, potentially benefiting patients with unmet medical needs.

Next Steps

• Gilead Sciences is expected to progress the KT-200 program into IND-enabling studies to support an IND filing in 2027.
• Sanofi plans to advance the IRAK4 degrader, KT-485/SAR447971, into clinical testing in 2026.
• The company expects to advance at least one new molecular entity into clinical testing annually.
• The company will continue to fund research and development costs with existing cash, cash equivalents, and marketable securities, or through strategic financing opportunities.

Key Dates

Recommendation

Kymera Therapeutics presents a mixed financial picture with increasing collaboration revenue and a strong cash position, but also growing operating expenses and net losses. The company's pipeline is in early stages, and its success hinges on clinical trial outcomes and future funding. While the Gilead milestone is positive, the overall financial trend warrants a cautious 'hold' until further clinical progress and revenue generation are demonstrated.

Keywords

Kymera Therapeutics, 10-Q, SEC Filing, Biopharmaceutical, Clinical Stage, Targeted Protein Degradation, Drug Development, Research and Development, Financial Results, Collaboration Revenue, Net Loss, Cash Reserves, Gilead Sciences, Sanofi